Chen · BMC gastroenterology 2025 · systematic review and meta-analysis of RCTs · n=5

Glutamine prevents diarrhea in colorectal cancer patients undergoing chemotherapy or chemoradiotherapy: a meta-analysis.

Cited 4 times in the scientific literature.

Level 1 - systematic review of randomized trials

Systematic review and meta-analysis of randomized controlled trials

PubMed 41053591 · doi:10.1186/s12876-025-04308-w · record verified 2026-08-30

What was done

A systematic review and meta-analysis following PRISMA 2020 guidelines and registered on INPLASY (INPLASY202490057). The authors searched PubMed, Cochrane Library, EMBASE, CNKI, and Wanfang through August 1, 2024, for randomized controlled trials assessing glutamine supplementation in preventing chemotherapy- or chemoradiotherapy-induced diarrhea in colorectal cancer patients. Outcomes were pooled using relative risk (RR) or mean difference (MD) with 95% confidence intervals (CIs).

What was found

Across 5 included RCTs involving 311 patients: - Diarrhea incidence was significantly reduced with glutamine compared to control (RR = 0.72, 95% CI: 0.60–0.87, P < 0.01, I² = 37%). - Subgroup analysis showed glutamine reduced diarrhea in patients receiving chemotherapy alone (RR = 0.65, 95% CI: 0.43–0.98, P < 0.05, I² = 35%). - By tumor location, diarrhea was reduced in the colorectal cancer subgroup (RR = 0.65, 95% CI: 0.44–0.97, P < 0.05, I² = 30%), but not in the rectal cancer subgroup (P > 0.05). - D-xylose levels were significantly higher in the glutamine group (MD = 0.32, 95% CI: 0.14–0.51, P < 0.01, I² = 0%), and C-reactive protein levels were significantly lower (MD = 0.52, 95% CI: 0.32–0.72, P < 0.01, I² = 0%). - The certainty of evidence for diarrhea was rated as low.

Why it matters

Glutamine supplementation may help reduce gastrointestinal toxicity during colorectal cancer treatment, with the clearest benefit observed in patients receiving chemotherapy alone.

Limits

The meta-analysis is based on a small total sample size (5 trials, 311 patients), and the overall certainty of evidence was graded as low. Subgroup benefits were not observed in rectal cancer, and the abstract does not report specific glutamine doses, routes of administration, or chemotherapy regimens.

Cited by